BNA was developed by Israel-based ElMindA to map, monitor and understand electro-physiological activity in response to cognitive or physiological activity.
The system combines the temporal resolution of electroencephalography (EEG) and the spatial functional magnetic resonance imaging (fMRI).
Combining these elements gives a three-dimensional image of neuronal connectivity and synchronisation. This provides data on drug effects to support early stage development.
Kendle has exclusively licensed the system for its early stage development work. "BNA is faster, less expensive and more accessible than other brain imaging solutions currently on the market because all scanning can be done in house”, said Ed Sellers, vice president, early stage, Kendle.